{"id":64116,"date":"2026-04-28T11:38:48","date_gmt":"2026-04-28T03:38:48","guid":{"rendered":"https:\/\/flcube.com\/?p=64116"},"modified":"2026-04-28T11:38:50","modified_gmt":"2026-04-28T03:38:50","slug":"aureka-biotechnologies-secures-35m-series-a-financing-to-advance-auraide-platform-for-functional-antibody-design","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64116","title":{"rendered":"Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design"},"content":{"rendered":"\n<p><strong>Aureka Biotechnologies<\/strong>, a global leader in the <strong>Tech-Bio<\/strong> space, announced the completion of its <strong>Series A+ financing round<\/strong>, raising <strong>USD 35 million<\/strong> to accelerate the development of its proprietary <strong>AuraIDE platform<\/strong> for innovative functional antibody design.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financing-details\">Financing Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Amount Raised<\/strong><\/td><td>USD 35 million<\/td><\/tr><tr><td><strong>Round<\/strong><\/td><td>Series A+<\/td><\/tr><tr><td><strong>Lead Investor<\/strong><\/td><td>HongShan<\/td><\/tr><tr><td><strong>Participating Investors<\/strong><\/td><td>Matrix Partners China, BioTrack Capital<\/td><\/tr><tr><td><strong>Existing Investors<\/strong><\/td><td>5Y Capital, Qiming Venture Partners, NRL Capital<\/td><\/tr><tr><td><strong>Company Founded<\/strong><\/td><td>2023<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-capital-allocation\">Strategic Capital Allocation<\/h2>\n\n\n\n<p>The proceeds will be strategically deployed across multiple critical areas:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AuraIDE Platform Enhancement<\/strong>: Advancing proprietary functional antibody design capabilities<\/li>\n\n\n\n<li><strong>AI Infrastructure<\/strong>: Strengthening foundation model and agent capabilities<\/li>\n\n\n\n<li><strong>Experimental Platform<\/strong>: Enhancing high-throughput, high-content experimental infrastructure<\/li>\n\n\n\n<li><strong>Pipeline Acceleration<\/strong>: Streamlining the continuum from project initiation through molecular design, drug development, and translational implementation<\/li>\n\n\n\n<li><strong>Clinical Transition<\/strong>: Accelerating diverse innovative drug pipelines into clinical stage<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platform-amp-innovation\">Technology Platform &amp; Innovation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Capability<\/th><th>Description<\/th><th>Competitive Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>AuraIDE Platform<\/strong><\/td><td>Proprietary functional antibody design system<\/td><td>Differentiated antibody discovery and optimization<\/td><\/tr><tr><td><strong>Data Flywheel<\/strong><\/td><td>High-throughput, high-content experimental data generation driving model-experiment co-evolution<\/td><td>Continuous improvement loop between AI models and wet lab validation<\/td><\/tr><tr><td><strong>Global Operations<\/strong><\/td><td>R&amp;D centers and high-throughput platforms in both China and United States<\/td><td>Access to diverse talent pools and regulatory environments<\/td><\/tr><tr><td><strong>Tech-Bio Integration<\/strong><\/td><td>Seamless integration of AI\/ML with experimental biology<\/td><td>Faster iteration cycles and reduced development timelines<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-position-amp-strategic-outlook\">Market Position &amp; Strategic Outlook<\/h2>\n\n\n\n<p>Founded in 2023, Aureka has rapidly established itself as a pioneer in the convergence of artificial intelligence and biotechnology. The company&#8217;s unique approach of continuously redefining functional data generation creates a self-reinforcing cycle where experimental results improve AI models, which in turn generate better molecular designs for experimental validation.<\/p>\n\n\n\n<p>The substantial backing from leading Chinese and international venture capital firms reflects strong confidence in Aureka&#8217;s technology platform and its potential to disrupt traditional antibody discovery paradigms. The dual-continent operational model provides strategic advantages in accessing both Western and Asian markets, talent, and regulatory pathways.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investment-thesis\">Investment Thesis<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Validation<\/strong>: Strong investor consortium validates the Tech-Bio convergence thesis<\/li>\n\n\n\n<li><strong>Scalable Infrastructure<\/strong>: High-throughput experimental platforms enable rapid pipeline expansion<\/li>\n\n\n\n<li><strong>Differentiated Approach<\/strong>: Co-evolution of models and experiments creates sustainable competitive moat<\/li>\n\n\n\n<li><strong>Market Timing<\/strong>: Growing demand for innovative antibody therapeutics aligns with platform capabilities<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding financing utilization, platform development, and pipeline advancement. Actual outcomes may differ due to risks including technical challenges, regulatory requirements, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aureka Biotechnologies, a global leader in the Tech-Bio space, announced the completion of its Series&#8230;<\/p>\n","protected":false},"author":1,"featured_media":64118,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2705],"class_list":["post-64116","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-aureka-biotechnologies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Aureka Biotechnologies, a global leader in the Tech-Bio space, announced the completion of its Series A+ financing round, raising USD 35 million to accelerate the development of its proprietary AuraIDE platform for innovative functional antibody design.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64116\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design\" \/>\n<meta property=\"og:description\" content=\"Aureka Biotechnologies, a global leader in the Tech-Bio space, announced the completion of its Series A+ financing round, raising USD 35 million to accelerate the development of its proprietary AuraIDE platform for innovative functional antibody design.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64116\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-28T03:38:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-28T03:38:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2802.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64116#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64116\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design\",\"datePublished\":\"2026-04-28T03:38:48+00:00\",\"dateModified\":\"2026-04-28T03:38:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64116\"},\"wordCount\":403,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64116#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2802.webp\",\"keywords\":[\"Aureka Biotechnologies\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64116#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64116\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64116\",\"name\":\"Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64116#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64116#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2802.webp\",\"datePublished\":\"2026-04-28T03:38:48+00:00\",\"dateModified\":\"2026-04-28T03:38:50+00:00\",\"description\":\"Aureka Biotechnologies, a global leader in the Tech-Bio space, announced the completion of its Series A+ financing round, raising USD 35 million to accelerate the development of its proprietary AuraIDE platform for innovative functional antibody design.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64116#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64116\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64116#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2802.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2802.webp\",\"width\":1080,\"height\":608,\"caption\":\"Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64116#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design - Insight, China&#039;s Pharmaceutical Industry","description":"Aureka Biotechnologies, a global leader in the Tech-Bio space, announced the completion of its Series A+ financing round, raising USD 35 million to accelerate the development of its proprietary AuraIDE platform for innovative functional antibody design.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64116","og_locale":"en_US","og_type":"article","og_title":"Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design","og_description":"Aureka Biotechnologies, a global leader in the Tech-Bio space, announced the completion of its Series A+ financing round, raising USD 35 million to accelerate the development of its proprietary AuraIDE platform for innovative functional antibody design.","og_url":"https:\/\/flcube.com\/?p=64116","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-28T03:38:48+00:00","article_modified_time":"2026-04-28T03:38:50+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2802.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64116#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64116"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design","datePublished":"2026-04-28T03:38:48+00:00","dateModified":"2026-04-28T03:38:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64116"},"wordCount":403,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=64116#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2802.webp","keywords":["Aureka Biotechnologies"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64116#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64116","url":"https:\/\/flcube.com\/?p=64116","name":"Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=64116#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=64116#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2802.webp","datePublished":"2026-04-28T03:38:48+00:00","dateModified":"2026-04-28T03:38:50+00:00","description":"Aureka Biotechnologies, a global leader in the Tech-Bio space, announced the completion of its Series A+ financing round, raising USD 35 million to accelerate the development of its proprietary AuraIDE platform for innovative functional antibody design.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64116#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64116"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=64116#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2802.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2802.webp","width":1080,"height":608,"caption":"Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64116#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2802.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64116","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64116"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64116\/revisions"}],"predecessor-version":[{"id":64119,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64116\/revisions\/64119"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/64118"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64116"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64116"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64116"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}